The small molecule inhibitor, NCT-503, not only targets PHGDH, the rate limiting enzyme in de novo serine synthesis, but also induces a remodelling of glucose-derived carbon flow into the TCA cycle independently of PHGDH expression in neuroblastoma cells. The gene discussed is PHGDH; the disease is neuroblastoma.